NEWTON, Mass., Nov. 10, 2020 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced that
Michael Kauffman, MD, PhD, Chief
Executive Officer of Karyopharm, will participate in a fireside
chat at the Jefferies 2020 Virtual London Healthcare Conference on
Tuesday, November 17, 2020 at
1:45 p.m. ET.
A live webcast of the fireside chat can be accessed under
"Events & Presentations" in the Investor section of the
Company's
website, http://investors.karyopharm.com/events-presentations.
A replay of the webcast will be archived on the Company's website
for 90 days following the fireside chat.
About Karyopharm Therapeutics
Karyopharm Therapeutics
Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company
pioneering novel cancer therapies and dedicated to the discovery,
development, and commercialization of novel first-in-class drugs
directed against nuclear export and related targets for the
treatment of cancer and other major diseases. Karyopharm's
Selective Inhibitor of Nuclear Export (SINE) compounds function by
binding with and inhibiting the nuclear export protein XPO1 (or
CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), received
accelerated approval from the U.S. Food and Drug Administration
(FDA) in July 2019 in combination
with dexamethasone as a treatment for patients with heavily
pretreated multiple myeloma. In June
2020, XPOVIO was approved by the FDA as a treatment for
patients with relapsed or refractory diffuse large B-cell lymphoma.
A Marketing Authorization Application for selinexor for patients
with heavily pretreated multiple myeloma is also currently under
review by the European Medicines Agency. In addition to
single-agent and combination activity against a variety of human
cancers, SINE compounds have also shown biological activity in
models of neurodegeneration, inflammation, autoimmune disease,
certain viruses and wound-healing. Karyopharm has several
investigational programs in clinical or preclinical development.
For more information, please visit
www.karyopharm.com.
View original
content:http://www.prnewswire.com/news-releases/karyopharm-to-participate-at-jefferies-2020-virtual-london-healthcare-conference-301168808.html
SOURCE Karyopharm Therapeutics Inc.